Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

Company Overview

Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage. Maralixibat has achieved regulatory approval in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome and is under review or in clinical development for other rare cholestatic conditions, including progressive familial intrahepatic cholestasis (PFIC). In addition to its lead compound, Mirum maintains a pipeline of product candidates aimed at expanding the therapeutic options available to patients with orphan liver diseases.

Founded in 2016 and headquartered in Brisbane, California, Mirum Pharmaceuticals operates with a patient-centric approach that emphasizes collaboration with advocacy groups and key opinion leaders in hepatology. Under the leadership of President and Chief Executive Officer Derek Chalmers, the company is actively pursuing regulatory approvals and commercial partnerships to bring its therapies to patients in the United States and international markets.

Key Stats

• Today's Range: $71.26 to $72.98
• 50-Day Range: $51.12 to $77.69
• 52-Week Range: $36.88 to $78.10
• Volume: 779,857 shs
• Average Volume: 721,391 shs
• Market Capitalization: $3.60 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $76.50
• Consensus Rating: Buy

Mirum Pharmaceuticals Stock Analysis - MarketRank™

Mirum Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 367th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Buy

Consensus Rating

Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Mirum Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Mirum Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mirum Pharmaceuticals is -59.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mirum Pharmaceuticals is -59.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mirum Pharmaceuticals has a P/B Ratio of 15.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.93% of the outstanding shares of Mirum Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Mirum Pharmaceuticals has recently increased by 9.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mirum Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Mirum Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.69

Percentage of Shares Shorted

14.93% of the outstanding shares of Mirum Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Mirum Pharmaceuticals has recently increased by 9.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.45

News Sentiment

Mirum Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Mirum Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,313,448.00 in company stock.

Percentage Held by Insiders

14.36% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

MIRM Stock Analysis - Frequently Asked Questions

How have MIRM shares performed this year?

Mirum Pharmaceuticals' stock was trading at $41.35 on January 1st, 2025. Since then, MIRM stock has increased by 73.5% and is now trading at $71.75.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) released its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.19. The firm's revenue was up 64.1% compared to the same quarter last year.
Read the conference call transcript.

When did Mirum Pharmaceuticals IPO?

Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 8/06/2025
• Today: 10/02/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MIRM
• CIK: 1759425
• Web: mirumpharma.com
• Phone: (650) 667-4085
• Fax: N/A
• Employees: 140
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Mirum Pharmaceuticals: $76.50
• High Price Target: $95.00
• Low Price Target: $49.00
• Potential Upside/Downside: +6.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.18
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$87.94 million
• Net Margins: -13.65%
• Pretax Margin: -13.37%
• Return on Equity: -24.76%
• Return on Assets: -8.50%

Debt

• Debt-to-Equity Ratio: 1.21
• Current Ratio: 3.13
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $336.89 million
• Price / Sales: 10.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.70 per share
• Price / Book: 15.27

Miscellaneous

• Outstanding Shares: 50,240,000
• Free Float: 43,024,000
• Market Cap: $3.60 billion
• Optionable: Optionable
• Beta: 0.81